Business
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at $2.25 per share, representing a 68% premium to the March 17, 2026 closing price– - Financing includes 50% warrant coverage priced at $5 per share, representing a 273% premium to market, if exercised would raise up to an additional $33.3 million, extending runway into 2H 2027 - - P
About this update from Serina Therapeutics, Inc.
[{"type":"image","alt":"Serina Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Serina Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/339c0b6f27c396eb444a95862a9f2125"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_rHPxM0Wn47pB..RwGicrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/339c0b6f27c396eb444a95862a9f2125","width":300,"height":88}},"lazy":false},{"type":"text","content":"- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at $2.25 per share, representing a 68% premium to the March 17, 2026 closing price–","length":299,"tagName":"p"},{"type":"text","content":"- Financing includes 50% warrant coverage priced at $5 per share, representing a 273% premium to market, if exercised would raise up to an additional $33.3 million, extending runway into 2H 2027 -","length":196,"tagName":"p"},{"type":"text","content":"- Proceeds to support ongoing single-ascending dose (SAD) registrational study arm under 505(b)(2) NDA pathway –","length":112,"tagName":"p"},{"type":"text","content":"HUNTSVILLE, AL, March 18, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced today that it has entered into definitive agreements for the private placement of common stock and pre-funded warrants raising $15 million in gross proceeds. This first tranche is expected to close on March 20, 2026. A second funding tranche of up to an additional $15 million is anticipated to close on or before April 30, 2026. The financing structure includes 50% warrant coverage with additional potential proceeds of up to $33.3 million from the future exercise of warrants. The transaction is led by Greg Bailey, M.D., a current Board Director who will assume the role of Co-Chairman of the Board of Directors.","length":873,"tagName":"p"},{"type":"text","content":"“With the first patient dosed in our registrational trial and a clear 505(b)(2) pathway aligned with the FDA, this financing p...